AT A GLANCE Project Information
Project Title: Nanosolutions: Biological Foundation for the Safety Classification of Engineered Nanomaterials (ENM): Systems Biology Approaches to Understand Interactions of ENM with Living Organisms and the Environment
Project Objective: By identifying and elaborating those characteristics of engineered nanomaterials (ENM) that determine their biological hazard potential, NANOSOLUTIONS FP7 will provide a means to develop a safety classification model for ENM based on an understanding of their interactions with living organisms at the molecular, cellular, and organism levels based on their material characteristics.
Haemoglobin, which carries oxygen through the bloodstream, is 5nm in diameter and controls the body’s many systems and processes
Project Duration and Timing: 4 years, April 2013 to April 2017
Project Funding: European Commission
largely governed by their surface properties. The overarching objective of this research
is, therefore, to provide a means to develop an “ENM safety classifier” based on their material characteristics, using the understanding of ENM interactions with living organisms at the molecular, cellular and organism level acquired in this consortium. This will give scientists the ability to predict these harmful effects rather than simply describe them once they have occurred. The Nanosolutions ENM safety
classification model will be of great benefit not only to industry, but also in enabling and speeding up innovation. By making the innovation cycle quicker and making it
AT A GLANCE MAIN CONTACT
Kai Savolainen Kai Savolainen, MD, is currently Professor and Director of Nanosafety Research Centre at the Finnish Institute of Occupational Health. His research interests cover inflammatory and genetic effects and risk assessment of engineered nanomaterials. He has served in numerous scientific expert committees, and has led several international and national research consortia
www.projectsmagazine.eu.com
with a focus on the safety of engineered nanoparticles.
Contact: Tel: +358 40 742 0574 Email:
kai.savolainen@
ttl.fi Web:
www.nanosolutionsfp7.com
easier to develop commercially viable products that use ENM, Nanosolutions will deliver results critical for maintaining Europe’s position in the nanotechnology field. As a result of the project, testing procedure will be shorter and more cost effective. The public will have greater confidence in the products produced using ENM, thus making them more commercially viable. Industry will be more inclined to use innovative technology in their product development if they can assure its safety and they know consumer concerns are abated. The work Nanosolutions does will be vital in bringing new materials and technologies to market.
★
Project Partners: FIOH, Karolinska Institutet, NUID UCD, TNO, Universite Bordeaux, University of Manchester, University of Plymouth, Heriot-Watt University, CIC biomaGUNE, Walter Brendel Centre of Experimental Medicine, IOM, Turku Centre for Biotechnology, VTT, LEITAT, DTU Food, TIGEM, ULEI, Empa, Biobyte Solutions GmbH, Insight Publishers, PlasmaChem GmbH, Inkoa, BioTeSys GmbH, Zhejiang University, FUB, NHLS/NIOH, North West University, NCL / SAIC Frederick Inc., Nanocyl SA, Nanologica AB, NeuRoNe lab, University of Salerno, SOLVAY, Polymer Factory Sweden AB, Polysistec
97
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112